New era of the treatment against hepatitis C virus
Natsuizaka, M.; Sakamoto, N.
Nihon Rinsho. Japanese Journal of Clinical Medicine 73(2): 317-321
2015
ISSN/ISBN: 0047-1852 PMID: 25764689 Document Number: 680917
Interferon (IFN) and ribavirin (RBV) have remained as key drugs in the treatment against hepatitis C virus (HCV) for a past decade. Although the IFN and RBV based therapy has been greatly improved, indication of the IFN based therapy is limited because of its side effects. Thus, new types of drugs against HCV have been awaited. Now many direct acting antivirals (DAAs) targeting protease, NS5A and polymerase of HCV have been developed and many clinical trials with new DAAs are ongoing. Furthermore, some of the trials have already shown outstanding results with high curative rate reaching almost 100% and very low rate of adverse events. The IFN free regimens with new DAAs would completely change the treatment against HCV.
Document emailed within 1 workday
Related Documents
Tung, H.-D.; Lu, S.-N.; Lee, C.-M.; Wang, J.-H.; Chen, T.-M.; Hung, C.-H.; Huang, W.-S.; Changchien, C.-S. 2002: Antiviral treatment responses in patients with chronic hepatitis C virus infection evaluated by a third generation anti-hepatitis C virus assay Journal of Viral Hepatitis 9(4): 304-308Roux, P.; Fugon, L.; Winnock, M.; Salmon-Céron, D.; Lacombe, K.; Sogni, P.; Spire, B.; Dabis, F.ço.; Carrieri, M.P. 2012: Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users Addiction 107(1): 152-159
Sakuma, I.; Enomoto, N.; Asahina, Y.; Kurosaki, M.; Sato, C. 1995: Fluctuation of hepatitis C virus quasispecies with interferon treatment and interferon-resistant variants in hepatitis C virus 1b Nihon Rinsho. Japanese Journal of Clinical Medicine 53 Suppl (Part 1): 930-935
Sungkanuparph, S.; Vibhagool, A.; Manosuthi, W.; Kiertiburanakul, S.; Atamasirikul, K.; Aumkhyan, A.; Thakkinstian, A. 2004: Prevalence of hepatitis B virus and hepatitis C virus co-infection with human immunodeficiency virus in Thai patients: a tertiary-care-based study Journal of the Medical Association of Thailand 87(11): 1349-1354
Adoga, M.P.; Banwat, E.B.; Forbi, J.C.; Nimzing, L.; Pam, C.R.; Gyar, S.D.; Agabi, Y.A.; Agwale, S.M. 2009: Human immunonodeficiency virus, hepatitis B virus and hepatitis C virus: sero-prevalence, co-infection and risk factors among prison inmates in Nasarawa State, Nigeria Journal of Infection in Developing Countries 3(7): 539-547
Calderón, G.M.; González-Velázquez, F.; González-Bonilla, C.R.; Novelo-Garza, B.ár.; Terrazas, J.J.; Martínez-Rodríguez, M.L.; Cortés-Márquez, S.R.; Blanco-Flores, J.P.; Rodríguez-Rodríguez, A.; Del Campo, M.A.; Cortés-Gómez, R.; Mejía-Bocanegra, M.G. 2009: Prevalence and risk factors of hepatitis C virus, hepatitis B virus, and human immunodeficiency virus in multiply transfused recipients in Mexico Transfusion 49(10): 2200-2207
Kazi, A.M.; Shah, S.A.; Jenkins, C.A.; Shepherd, B.E.; Vermund, S.H. 2010: Risk factors and prevalence of tuberculosis, human immunodeficiency virus, syphilis, hepatitis B virus, and hepatitis C virus among prisoners in Pakistan International Journal of Infectious Diseases: Ijid: Official Publication of the International Society for Infectious Diseases 14(Suppl 3): E60-E66
Chung, D.C.; Ko, Y.C.; Chen, C.J.; Chen, E.R.; Wu, C.C.; Wu, P.S. 1989: Seroepidemiology of hepatitis B virus, hepatitis D virus, and human immunodeficiency virus infections among parenteral drug abusers in southern Taiwan Journal of Medical Virology 28(4): 215-218
Sutcliffe, S.; Taha, T.E.; Kumwenda, N.I.; Taylor, E.; Liomba, G.N. 2002: HIV-1 prevalence and herpes simplex virus 2, hepatitis C virus, and hepatitis B virus infections among male workers at a sugar estate in Malawi Journal of Acquired Immune Deficiency Syndromes 31(1): 90-97
Villari, D.; Pernice, M.; Spinella, S.; Squadrito, G.; Rodinò, G.; Brancatelli, S.; Longo, G.; Raimondo, G. 1995: Chronic hepatitis in patients with active hepatitis B virus and hepatitis C virus combined infections: a histological study American Journal of Gastroenterology 90(6): 955-958
Ruzibakiev, R.; Kato, H.; Ueda, R.; Yuldasheva, N.; Hegay, T.; Avazova, D.; Kurbanov, F.; Zalalieva, M.; Tuichiev, L.; Achundjanov, B.; Mizokami, M. 2001: Risk factors and seroprevalence of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection in uzbekistan Intervirology 44(6): 327-332
Kania, D.; Sangaré, L.; Sakandé, J.; Koanda, A.; Nébié, Y.K.; Zerbo, O.; Combasséré, A.W.; Guissou, I.P.; Rouet, F.ço. 2009: A new strategy to improve the cost-effectiveness of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and syphilis testing of blood donations in sub-Saharan Africa: a pilot study in Burkina Faso Transfusion 49(10): 2237-2240
Devi, K.S.; Singh, N.B.; Singh, H.L.; Singh, Y.M. 2009: Coinfection by human immunodeficiency virus, hepatitis B virus and hepatitis C virus in injecting drug users Journal of the Indian Medical Association 107(3): 144; 146-147
Guido, M.; Rugge, M.; Colombari, R.; Cecchetto, A.; Scarpa, A.; Cadrobbi, P. 1998: Prompt hepatitis C virus suppression following hepatitis B virus superinfection in chronic untreated hepatitis C Italian Journal of Gastroenterology and Hepatology 30(4): 414-417
Baba, T.; Makino, R.; Shibata, M.; Harada, E.; Mitamura, K. 1997: Interferon treatment for hepatitis G virus infection in patients with chronic hepatitis C Nihon Rinsho. Japanese Journal of Clinical Medicine 55(3): 625-630
Teuber, G.; Dienes, H.P.; Meyer zum Büschenfelde, K.H.; Gerken, G. 1995: Hepatitis B virus superinfection in a patient with chronic hepatitis C receiving alpha-interferon treatment Hepato-Gastroenterology 42(2): 189-191
Wiegand, J.; Hasenclever, D.; Tillmann, H.L. 2008: Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence Antiviral Therapy 13(2): 211-220
Panlilio, A.L.; Shapiro, C.N.; Schable, C.A.; Mendelson, M.H.; Montecalvo, M.A.; Kunches, L.M.; Perry, S.W.; Edwards, J.R.; Srivastava, P.U.; Culver, D.H. 1995: Serosurvey of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among hospital-based surgeons. Serosurvey Study Group Journal of the American College of Surgeons 180(1): 16-24
Pivert, A.; Payan, C.; Lunel, F.; C, E.R.T. A. 2004: Comparaison des cinétiques de l'ARN et de l'antigène de capside du virus de l'hépatite C dans le suivi thérapeutique des patients co-infectés par le virus de l'hépatite C et le virus de l'immunodéficience humaine, traités par bithérapie interféron-ribavirine, dans le cadre du protocole RIBAVIC - Comparison of hepatitis C viral RNA and core antigen kinetics in the therapeutic follow up of hepatitis C virus and human immunodeficiency virus co-infected patients, treated by bitherapy interferon-ribavirin, within the framework of RIBAVIC protocol Pathologie et Biologie 52(9): 522-528
Lei, C.-l.; Huang, C.-h.; Yang, Z.; Tang, X.-p. 2007: Induction of specific cytotoxic T lymphocyte response against hepatitis B virus by hepatitis B virus S gene-modified dendritic cells Zhonghua Shi Yan he Lin Chuang Bing du Xue Za Zhi 21(2): 108-110